After CAR T therapy, seven women with severe autoimmune disease had healthy newborns

After CAR T cell therapy for severe autoimmune disease, seven women had healthy newborns and five more were in normal pregnancies as of late May, according to a study published July 29 in the New England Journal of Medicine and reported by Science News. The cohort is small, the follow-up is short, and the treatment still carries infection and other serious risks. For reproductive-age patients who have been told to assume that an immune-reset therapy and a pregnancy are incompatible, this is the first cohort-scale evidence that the question is answerable.

The participants were largely women with lupus, drawn from six countries: Germany, Belgium, China, Switzerland, France, and the United States. The babies were born in 2025 and 2026. Pregnancies began naturally between one month and three and a half years after treatment. All participants were in remission at conception. None experienced autoimmune reactivation during pregnancy. The seven newborns had normal birth weights and no infections at birth, and immune-protein testing on five matched healthy newborns.

CAR T cell therapy engineers a patient's T cells to destroy the B cells that attack the body's own tissue. Bone marrow eventually repopulates the B-cell pool, but without the self-sabotaging lineages. In the original cancer use case, recipients are often past reproductive age or on concurrent chemotherapy, which is why pregnancy reports from that population are rare. The autoimmune cohort in the new study is different on both counts: the patients are younger, and they are not on the toxic drug regimens that accompanied early CAR T.

Lead author Georg Schett, an immunologist at Friedrich-Alexander-Universität Erlangen-Nürnberg in Germany, has tracked this line of treatment since a 2022 report on five lupus patients who entered remission after CAR T. A 2024 case report in Clinical and Experimental Rheumatology added a single pregnancy to the record. The new NEJM paper is the first to aggregate pregnancy outcomes across multiple centers.

The data shift the family-planning conversation. Untreated autoimmune disease carries documented pregnancy risks: miscarriage, preterm birth, and low birth weight. Until now, the choice for women with severe disease was either to attempt pregnancy while their condition was still active, or to treat the disease aggressively and accept that the immune-reset path might close off a family. The new data do not resolve that choice and do not endorse CAR T as safe in pregnancy. They do move the question from a default "no" to a real conversation between patient and rheumatologist about timing, remission status, and the risks the treatment itself still carries.

The caveats are real. Seven births is a signal, not a population estimate. There is no control group. The cohort only included patients in remission at conception, which is a pregnancy in a patient whose disease was severe enough to warrant the therapy in the first place. Newborn follow-up is short. The treatment itself can cause infection, cytokine release syndrome, and other potentially serious side effects. Pregnancy safety signals from lupus patients in remission do not automatically transfer to other autoimmune indications, or to patients whose disease is active at conception.

The team is continuing to enroll. The next test is duration: whether the immune-protein match holds as the children grow, and whether larger, controlled cohorts confirm what seven births and five ongoing pregnancies now suggest.